Pipeline
Complement Therapeutics is advancing a focused pipeline of next-generation cell and gene therapy programmes targeting sight-threatening disease. Our pipeline is built on deep expertise in complement biology and guided by a disciplined translational and clinical development strategy.
A focused, clinically driven development strategy
Our programmes are designed to address clearly defined disease mechanisms within the complement system, with each advancing through structured discovery, preclinical, and clinical development stages. Progression is guided by robust scientific validation, regulatory alignment, and long-term patient impact.
Pipeline Snapshot
CTx001 is an adeno-associated virus (AAV) gene therapy programme for geographic atrophy secondary to AMD, currently in Phase I/II clinical development.
Programme - CTx001
CTx001 is Complement Therapeutics’ lead gene therapy programme, designed to address diseases driven by dysregulation of the complement system. The programme applies a gene-based approach to enable sustained local modulation of complement activity within the eye, reflecting the chronic nature of geographic atrophy and the need for long-term therapeutic intervention.
Indication
CTx001 is Complement Therapeutics’ lead gene therapy programme, designed to address diseases driven by dysregulation of the complement system. The programme applies a gene-based approach to enable sustained local modulation of complement activity within the eye, reflecting the chronic nature of geographic atrophy and the need for long-term therapeutic intervention.
Stage
CTx001 is currently in Phase I/II clinical development, including first-in-human evaluation. This stage of development is focused on assessing safety and tolerability, alongside the collection of early clinical and biological data to inform further clinical development.
A focused, clinically driven development strategy
Our programmes are designed to address clearly defined disease mechanisms within the complement system, with each advancing through structured discovery, preclinical, and clinical development stages. Progression is guided by robust scientific validation, regulatory alignment, and long-term patient impact.
Development stages
Complement Therapeutics applies a structured development framework, with each programme progressing through defined scientific, translational, and regulatory milestones. Advancement between stages is driven by data quality, clinical relevance, and patient safety considerations.
Discovery and validation
Preclinical development
IND-enabling activities
Clinical evaluation
From complement biology to clinical development
The pipeline is built on Complement Therapeutics’ deep understanding of complement system biology and its role in ocular disease. This scientific foundation informs programme design, target selection, and development strategy, enabling assets to progress through defined translational and regulatory milestones toward clinical evaluation.
Complement applies a disciplined, data-driven approach to advancement, with progression guided by scientific validation, clinical relevance, and patient safety considerations.
Our Offices & Labs
Munich, Germany
Headquarters
London, UK
Imperial College Campus
Stevenage, UK
Stevenage Bioscience Catalyst
Explore our research and development programmes or contact the team regarding scientific collaboration, partnerships, or general enquiries.
